Ultragenyx to sell rare pediatric disease priority review voucher for $203 million
Bitget2026/10/14 12:32- Ultragenyx signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 203 million.
- The voucher was awarded on FDA clearance of FAYUVI (UX111) for mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome Type A.
- Closing remains subject to customary conditions, including expiration of the Hart-Scott-Rodino waiting period.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
15.49 trillion! BlackRock's assets under management have reached half of the US GDP
BlackRock recorded net inflows of $205 billions in the third quarter, with revenue rising 19% year-on-year to $7.75 billions. The flagship iShares ETF attracted more than $135 billions, while net inflows for private credit increased by $5 billions quarter-on-quarter. CEO Larry Fink stated that the company is entering the fourth quarter with accelerating momentum and solid reserves in the private market and pension fund businesses. However, Moody's warned that risks are still accumulating in the private credit market under the high interest rate environment.
The address associated with the Worldcoin project deposited 14.475 million WLD to an exchange within 24 hours.
Up over 100%, five wallets long 50.17 million AGT with 2x leverage, yielding a floating profit of $887,000
Crypto prices
More
